(1) Pulmonary artery hypertension |
|
(1.1) Idiopathic (IPAH) |
|
(1.2) Hereditary (HPAH)—BMPR2, ALK-1, endoglin |
|
(1.3) Drug and toxin induced |
|
(1.4) Associated pulmonary artery hypertension (APAH) |
|
(1.4.1) Connective tissue disorders |
|
(1.4.2) HIV infection |
|
(1.4.3) Portal hypertension |
|
(1.4.4) Congenital heart diseases |
|
(1.4.5) Schistosomiasis |
|
(1.4.6) Chronic hemolytic anemia |
|
(1.4.7) Persistent newborn pulmonary hypertension |
|
(1.5) Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PCH) |
|
(2) Pulmonary hypertension caused by left-heart disease |
|
(2.1) Systolic dysfunction |
|
(2.2) Diastolic dysfunction |
|
(2.3) Valve disease |
|
(3) Pulmonary hypertension secondary to pulmonary diseases and/or hypoxemia |
|
(3.1) Chronic obstructive pulmonary disease |
|
(3.2) Interstitial pulmonary disease |
|
(3.3) Other pulmonary diseases with mixed restrictive and obstructive patterns |
|
(3.4) Sleep-disordered breathing |
|
(3.5) Alveolar hypoventilation disorders |
|
(3.6) Chronic high-altitude exposure |
|
(3.7) Developmental abnormalities |
|
(4) Chronic thromboembolic pulmonary hypertension (CTEPH) |
|
(5) Pulmonary hypertension with unclear or multifactorial mechanisms |
|
(5.1) Hematological disorders: myeloproliferative and splenectomy |
|
(5.2) Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, and vasculitis |
|
(5.3) Metabolic disorders: glycogen storage disease, Gaucher's disease, and thyroid disorders |
|
(5.4) Others: tumoral obstruction, fibrous mediastinitis, and chronic renal failure with dialysis |
|